

# ACRO Panel discussion topics

### **3. How to ensure that key clinical trial information is publicly available while achieving a balanced protection of sponsors' legitimate economic interests?**

- Balance the value of transparency vs needs for confidentiality
- ACRO supports key aims of transparency but information in some documents may not add value to research community or participants.
  - IB, scientific advice, response to RFI, insurance, temporary halt notification, serious breach report or third country inspection report
  - Third party contact details
  - Focus information by reducing list of publishable documentation